Drugs / GS-2829
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05770895 | Apr 2023 → Jan 2025 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-2829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05770895 ↗ |
| Modality | Vaccine | “Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779” NCT05770895 ↗ |